Skip to main content
. 2006 Oct 18;2006(4):CD006060. doi: 10.1002/14651858.CD006060.pub2
Characteristic Mortality Morbidity Adverse events Notes
Aronoff 2000: 
 
 I1: pioglitazone 
 7.5 mg; 15 mg; 30 mg; 45 mg 
 C1: placebo not investigated not investigated see table 'Adverse events'  
Charbonnel 2005a: 
 
 I1: pioglitazone 
 C1: gliclazide not investigated not investigated see table 'Adverse events'  
Derosa 2004: 
 
 I1: pioglitazone + glimepiride 
 C1: rosiglitazone + glimepiride not investigated not investigated see table 'Adverse events'  
Derosa 2006: 
 
 I1: pioglitazone + metformin 
 C1: rosiglitazone + metformin not investigated not investigated see table 'Adverse events'  
Dormandy 2005: 
 
 I1: pioglitazone + other glucose‐lowering drugs 
 C1: placebo + other glucose‐lowering drugs Primary composite endpoint ‐ I1: 19.7% (514/2605) C1: 21.7% (572/2633) 
 HR 0.90 (95% CI 0.80 to 1.02, p=0.095) 
 "Main" secondary endpoint ‐ I1: 11.6% (301/2605) C1: 13.6% (358/2633) 
 HR 0.84 (95% CI 0.72 to 0.98, p=0.027) 
 [n] of first occurence of the individual components of the primary composite endpoint: 
 death ‐ I1: 177, C1: 186 ‐ HR 0.96 (95% CI 0.78 to 1.18); 
 non‐fatal myocardial infarction (including silent myocardial infarction) ‐ 
 I1: 119, C1: 144 ‐ HR 0.83 (95% CI 0.65 to 1.06); 
 stroke ‐ I1: 86; C1: 107 ‐ HR 0.81 (95% CI 0.61 to 1.07); 
 major leg amputation ‐ I1: 26, C1: 26 ‐ HR 1.01 (95% CI 0.58 to 1.73); 
 acute coronary syndrome ‐ I1: 56, C1: 72 ‐ HR 0.78 (95% CI 0.55 to 1.11); 
 coronary revascularisation ‐ I1: 169, C1: 193 ‐ HR 0.88 (95% CI 0.72 to 1.08); 
 leg revascularisation ‐ I1: 80, C1: 65 ‐ HR 1.25 (95% CI 0.90 to 1.73); 
 total ‐ I1: 803 events, C1: 900 events. see composite primary and secondary endpoints for mortality see table 'Adverse events'  
Ebeling 2001: 
 
 I1: pioglitazone 
 C1: glibenclamide 
 C2: placebo not investigated not investigated see table 'Adverse events'  
Goke 2002: 
 
 I1: pioglitazone 
 C1: acarbose not investigated not investigated see table 'Adverse events'  
Goldberg 2005: 
 
 I1: pioglitazone 
 C1: rosiglitazone not investigated not investigated see table 'Adverse events'  
Hanefeld 2004: 
 
 I1: pioglitazone + sulfonylureas 
 C1: metformin + sulfonylureas not investigated not investigated see table 'Adverse events'  
Jovanovic 2004: 
 
 I1: pioglitazone 
 C1: repaglinide 
 C2: repaglinide + pioglitazone not investigated not investigated see table 'Adverse events'  
Langenfeld 2005: 
 
 I1: pioglitazone 
 C1: glimepiride not investigated not investigated see table 'Adverse events'  
Lawrence 2004: 
 
 I1: pioglitazone 
 C1: metformin 
 C2: gliclazide not investigated not investigated see table 'Adverse events'  
Matthews 2005: 
 
 I1: pioglitazone + metformin 
 C1: gliclazide + metformin not investigated not investigated see table 'Adverse events'  
Mattoo 2005: 
 
 I1: pioglitazone + insulin 
 C1: placebo + insulin not investigated not investigated see table 'Adverse events'  
Pavo 2003: 
 
 I1: pioglitazone 
 C1: metformin not investigated not investigated see table 'Adverse events'  
Scherbaum 2002: 
 
 I1: pioglitazone 15mg 
 I2: pioglitazone 30mg 
 C1: placebo not investigated not investigated see table 'Adverse events'  
Schernthaner 2004: 
 
 I1: pioglitazone 
 C1: metformin not investigated not investigated see table 'Adverse events'  
Smith 2005: 
 
 I1: pioglitazone 
 C1: placebo not investigated not investigated see table 'Adverse events'  
Tan 2004a: 
 
 I1: pioglitazone 
 C1: glimepiride not investigated not investigated see table 'Adverse events'  
Tan 2004b: 
 
 I1: pioglitazone 
 C1: glibenclamide not investigated not investigated see table 'Adverse events'  
Watanabe 2005: 
 
 I1: pioglitazone 
 C1: glibenclamide not investigated not investigated see table 'Adverse events'  
Yamanouchi 2005: 
 
 I1: pioglitazone 
 C1: metformin 
 C2: glimepiride not investigated not investigated see table 'Adverse events'  
         
Symbols & abbreviations: ? = unclear; 
 I = intervention; C = control; 
 HR = hazard ratio; CI = confidence intervall